The industry could see payment, workforce and insurance coverage changes depending on how the Trump administration weighs in ...

Stock analysts at Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for Bristol-Myers Squibb in a note ...

Biotech companies saw the most notable insider purchases of the past week. A Mexican billionaire also continued to build a ...

William Blair reduced their Q1 2026 EPS estimates for Bristol-Myers Squibb in a research report issued to clients and ...

While smokable product sales are declining slowly, sales of non-smokable products are driving growth for Altria Group. The ...

A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The ...

"Woman," "elderly," and "disabled" were among a list of banned words reportedly circulating within the FDA, which the White ...

BridgeBio possesses a medium revenue cyclicality rating, and its operating leverage has a low rating. We assess the company's balance sheet as weak due to management's dependence on debt issuance to ...

Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...

With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine ...

With 2025 underway, the AFS Health Care team highlights some of the most pressing legal issues facing the health care industry this year.